Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Anti-VEGFs Have Reached Their Limit:’ EyeBio Targets New Pathway For Eye Therapies

Potential First-In-Class Wnt Agonist

Executive Summary

Led by the duo who brought the first anti-VEGF drug to market, EyeBio aims to develop the next breakthrough eye therapy via a novel tri-specific antibody.

You may also be interested in...



Europe’s Biotech Sector Still In Reasonable Shape

Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.

Finance Watch: Gilde Closes Sixth Venture Fund With €740m For Drugs, MedTech

Private Company Edition: The €740m ($806.5m) Gilde Healthcare Venture&Growth VI Fund will back companies in Europe and North America. Among recent financings, VectorY raised a €129m ($138m) series A round, EyeBio expanded its series A to $130m and MBrace raised an $85m series B.

Up Next For Roche In Ophthalmology: Nine Clinical-Stage Programs

Roche said it remains deeply committed to the therapeutic area and highlighted a broad clinical pipeline at a virtual investor event.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel